

Magnetic Resonance Perfusion and Permeability Imaging

Neuroimaging Clinics of North America

19, 527-557

DOI: [10.1016/j.nic.2009.08.007](https://doi.org/10.1016/j.nic.2009.08.007)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Advanced Contrast-Enhanced MR Imaging of the CNS. <i>Neuroradiology Journal</i> , 2010, 23, 525-534.	0.6	1
2	Comment to: Parametric Response Map as an Imaging Biomarker to Distinguish Progression from Pseudoprogession in High-Grade Glioma: Pitfalls in Perfusion MRI in Brain Tumors. <i>Klinische Neuroradiologie</i> , 2010, 20, 183-184.	0.9	10
3	New MR sequences (diffusion, perfusion, spectroscopy) in brain tumours. <i>Pediatric Radiology</i> , 2010, 40, 999-1009.	1.1	53
4	Arterial spin labeling in neuroimaging. <i>World Journal of Radiology</i> , 2010, 2, 384.	0.5	161
5	Magnetic Resonance Techniques for the Brainstem. <i>Seminars in Ultrasound, CT and MRI</i> , 2010, 31, 230-245.	0.7	18
6	Prospective Analysis of Parametric Response Mapâ€‘Derived MRI Biomarkers: Identification of Early and Distinct Glioma Response Patterns Not Predicted by Standard Radiographic Assessment. <i>Clinical Cancer Research</i> , 2011, 17, 4751-4760.	3.2	84
7	Diagnosing infection of the CNS with MRI. <i>Imaging in Medicine</i> , 2011, 3, 689-710.	0.0	3
8	Advances in ultra-high field MRI for the clinical management of patients with brain tumors. <i>Current Opinion in Neurology</i> , 2011, 24, 605-615.	1.8	34
9	T ₁ - and T ₂ *-Dominant Extravasation Correction in DSC-MRI: Part IIâ€‘Predicting Patient Outcome after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 2054-2064.	2.4	35
10	Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion. <i>Neuro-Oncology</i> , 2011, 13, 1037-1046.	0.6	103
11	Evolution of the bloodâ€‘brain barrier in newly forming multiple sclerosis lesions. <i>Annals of Neurology</i> , 2011, 70, 22-29.	2.8	137
12	Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. <i>NMR in Biomedicine</i> , 2011, 24, 734-749.	1.6	81
13	Perfusion and Permeability MR Imaging of Gliomas. <i>Technology in Cancer Research and Treatment</i> , 2011, 10, 59-71.	0.8	27
14	Advanced imaging of brain tumors. , 2012, , 188-213.		0
15	Musculoskeletal Tumors: How to Use Anatomic, Functional, and Metabolic MR Techniques. <i>Radiology</i> , 2012, 265, 340-356.	3.6	175
16	Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas. <i>Acta Radiologica</i> , 2012, 53, 95-101.	0.5	41
17	Biologic Imaging of Head and Neck Cancer: The Present and the Future. <i>American Journal of Neuroradiology</i> , 2012, 33, 586-594.	1.2	75
18	MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice. <i>American Journal of Neuroradiology</i> , 2012, 33, 803-817.	1.2	87

#	ARTICLE	IF	CITATIONS
19	The Added Value of Apparent Diffusion Coefficient to Cerebral Blood Volume in the Preoperative Grading of Diffuse Gliomas. American Journal of Neuroradiology, 2012, 33, 701-707.	1.2	119
20	Treatment-Related Change Versus Tumor Recurrence in High-Grade Gliomas: A Diagnostic Conundrum—Use of Dynamic Susceptibility Contrast-Enhanced (DSC) Perfusion MRI. American Journal of Roentgenology, 2012, 198, 19-26.	1.0	131
21	Glioblastoma blood flow measured with stable xenon CT indicates tumor necrosis, vascularity, and brain invasion. Neuro-Oncology, 2012, 14, 641-648.	0.6	2
22	The alphabet soup of perfusion CT and MR imaging: terminology revisited and clarified in five questions. Neuroradiology, 2012, 54, 907-918.	1.1	25
23	Quantitative analysis of neovascular permeability in glioma by dynamic contrast-enhanced MR imaging. Journal of Clinical Neuroscience, 2012, 19, 820-823.	0.8	54
24	Application of CT perfusion imaging to the histological differentiation of adrenal gland tumors. European Journal of Radiology, 2012, 81, 502-507.	1.2	14
25	Postoperative and Postradiation Changes on Imaging. Otolaryngologic Clinics of North America, 2012, 45, 1405-1422.	0.5	9
26	Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma. American Journal of Neuroradiology, 2012, 33, 1349-1355.	1.2	277
27	Diffusion Tensor and Perfusion Imaging of Brain Tumors in High-Field MR Imaging. Neuroimaging Clinics of North America, 2012, 22, 123-134.	0.5	35
28	Advanced Techniques Using Contrast Media in Neuroimaging. Magnetic Resonance Imaging Clinics of North America, 2012, 20, 699-713.	0.6	17
29	Delayed Contrast Extravasation MRI for Depicting Tumor and Non-Tumoral Tissues in Primary and Metastatic Brain Tumors. PLoS ONE, 2012, 7, e52008.	1.1	39
30	Pilot study on evaluation of any correlation between MR perfusion (Ktrans) and diffusion (apparent) Tj ETQq1 1 0.784314 rgBT /Overl	1.2	17
31	Clinical application of pharmacokinetic analysis as a biomarker of solitary pulmonary nodules: Dynamic contrast-enhanced MR imaging. Magnetic Resonance in Medicine, 2012, 68, 1614-1622.	1.9	19
32	Perfusion MRI: The Five Most Frequently Asked Clinical Questions. American Journal of Roentgenology, 2013, 201, W495-W510.	1.0	181
34	Protocolo de estudio por neuroimágenes de los tumores del sistema nervioso central. Neurologia Argentina, 2013, 5, 37-43.	0.1	2
35	Perfusion MRI: The Five Most Frequently Asked Technical Questions. American Journal of Roentgenology, 2013, 200, 24-34.	1.0	296
36	Posttreatment Evaluation of Central Nervous System Gliomas. Magnetic Resonance Imaging Clinics of North America, 2013, 21, 241-268.	0.6	11
37	Brain Tumors. Magnetic Resonance Imaging Clinics of North America, 2013, 21, 199-239.	0.6	49

#	ARTICLE	IF	CITATIONS
38	Validation of 18F-FDG PET at Conventional and Delayed Intervals for the Discrimination of High-Grade From Low-Grade Gliomas. <i>Clinical Nuclear Medicine</i> , 2013, 38, 495-500.	0.7	23
39	The Role of Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging in Differentiating between Infectious and Neoplastic Focal Brain Lesions: Results from a Cohort of 100 Consecutive Patients. <i>PLoS ONE</i> , 2013, 8, e81509.	1.1	31
40	Brain metastasis as initial presentation of papillary adenocarcinoma of the lung: case report. <i>Radiologia Brasileira</i> , 2013, 46, 313-316.	0.3	3
41	Glioma Grading Capability: Comparisons among Parameters from Dynamic Contrast-Enhanced MRI and ADC Value on DWI. <i>Korean Journal of Radiology</i> , 2013, 14, 487.	1.5	67
42	Original article Anaplastic transformation of low-grade gliomas (WHO II) on magnetic resonance imaging. <i>Folia Neuropathologica</i> , 2014, 2, 128-140.	0.5	20
44	Perfusion magnetic resonance imaging for high grade astrocytomas: Can cerebral blood volume, peak height, and percentage of signal intensity recovery distinguish between progression and pseudoprogression?. <i>Radiologia</i> , 2014, 56, 35-43.	0.3	10
45	Assessment of irradiated brain metastases using dynamic contrast-enhanced magnetic resonance imaging. <i>Neuroradiology</i> , 2014, 56, 437-43.	1.1	20
46	Analysis of diffusion tensor imaging metrics for gliomas grading at 3T. <i>European Journal of Radiology</i> , 2014, 83, e156-e165.	1.2	48
47	A Prognostic Model Based on Preoperative MRI Predicts Overall Survival in Patients with Diffuse Gliomas. <i>American Journal of Neuroradiology</i> , 2014, 35, 1096-1102.	1.2	58
48	Advanced Magnetic Resonance Imaging Methods for Planning and Monitoring Radiation Therapy in Patients With High-Grade Glioma. <i>Seminars in Radiation Oncology</i> , 2014, 24, 248-258.	1.0	18
49	Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. <i>Journal of Neuro-Oncology</i> , 2014, 120, 361-370.	1.4	18
50	Comparison of ¹⁸ F-FET PET and Perfusion-Weighted MR Imaging: A PET/MR Imaging Hybrid Study in Patients with Brain Tumors. <i>Journal of Nuclear Medicine</i> , 2014, 55, 540-545.	2.8	115
51	Novel Magnetic Resonance Imaging Techniques in Brain Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2015, 24, 137-146.	0.7	2
52	Imaging of the Posttherapeutic Brain. <i>Topics in Magnetic Resonance Imaging</i> , 2015, 24, 147-154.	0.7	9
53	Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced MR in Tumor Parenchyma and Peritumoral Area for Distinction of Brain Tumors. <i>PLoS ONE</i> , 2015, 10, e0138573.	1.1	39
54	Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging. <i>Cancer Imaging</i> , 2015, 15, 4.	1.2	97
55	Brain: Radiotherapy. <i>Medical Radiology</i> , 2015, , 45-59.	0.0	0
56	Delayed contrast extravasation MRI: a new paradigm in neuro-oncology. <i>Neuro-Oncology</i> , 2015, 17, 457-465.	0.6	66

#	ARTICLE	IF	CITATIONS
57	Principles of T ₂ *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 296-313.	1.9	112
58	Radiographic Detection and Advanced Imaging of Glioblastoma. , 2016, , 81-103.		0
59	Comparison of Cerebral Blood Volume and Plasma Volume in Untreated Intracranial Tumors. <i>PLoS ONE</i> , 2016, 11, e0161807.	1.1	10
60	Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis. <i>European Journal of Radiology</i> , 2016, 85, 1147-1156.	1.2	76
61	Medical Imaging Informatics. <i>Advances in Experimental Medicine and Biology</i> , 2016, 939, 167-224.	0.8	9
62	Magnetic Resonance Contrast Agents for Neuroradiology. , 2016, , 183-192.		0
63	Imaging of oligodendroglioma. <i>British Journal of Radiology</i> , 2016, 89, 20150857.	1.0	126
64	Multiparametric MR Imaging in the Assessment of Brain Tumors. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 87-122.	0.6	31
65	Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI. <i>American Journal of Neuroradiology</i> , 2016, 37, 28-36.	1.2	116
66	Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab. <i>Clinical and Translational Oncology</i> , 2017, 19, 51-57.	1.2	13
67	Advanced MRI Techniques in the Monitoring of Treatment of Gliomas. <i>Current Treatment Options in Neurology</i> , 2017, 19, 11.	0.7	58
68	Role of Dynamic Contrast-Enhanced Perfusion Magnetic Resonance Imaging in Grading of Pediatric Brain Tumors on 3T. <i>Pediatric Neurosurgery</i> , 2017, 52, 298-305.	0.4	15
70	Advanced MRI for Pediatric Brain Tumors with Emphasis on Clinical Benefits. <i>Korean Journal of Radiology</i> , 2017, 18, 194.	1.5	17
71	Neuroimaging: Techniques and General Applications. , 2017, , 209-224.		0
72	Brain Vascular Imaging Techniques. <i>International Journal of Molecular Sciences</i> , 2017, 18, 70.	1.8	35
73	Bases de la imagen funcional I: técnicas en uso clínico actualmente. <i>Radiología</i> , 2018, 60, 2-22.	0.3	3
74	Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice. <i>European Radiology</i> , 2018, 28, 3306-3317.	2.3	149
75	Current Clinical State of Advanced Magnetic Resonance Imaging for Brain Tumor Diagnosis and Follow Up. <i>Seminars in Roentgenology</i> , 2018, 53, 45-61.	0.2	10

#	ARTICLE	IF	CITATIONS
76	Differentiation of grade II/III and grade IV glioma by combining $\text{^{19}F}$ T1 contrast-enhanced brain perfusion imaging and susceptibility-weighted quantitative imaging. <i>Neuroradiology</i> , 2018, 60, 43-50.	1.1	27
77	Pseudoprogression of brain tumors. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 571-589.	1.9	199
78	Technical Aspects of Contrast-enhanced MR Angiography: Current Status and New Applications. <i>Magnetic Resonance in Medical Sciences</i> , 2018, 17, 3-12.	1.1	23
79	Surgical management of pediatric oligodendroglioma. , 2019, , 229-242.		0
80	Magnetic Resonance Imaging Parameters and Their Impact on Survival of Patients with Glioblastoma: Tumor Perfusion Predicts Survival. <i>World Neurosurgery</i> , 2019, 124, e285-e295.	0.7	1
81	Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting. <i>European Journal of Cancer</i> , 2019, 114, 89-96.	1.3	18
82	Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival. <i>Neurocirugia</i> , 2019, 30, 11-18.	0.2	10
83	Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival. <i>NeurocirugAa (English Edition)</i> , 2019, 30, 11-18.	0.1	2
84	Imaging of Central Nervous System Tumors Based on the 2016 World Health Organization Classification. <i>Neurologic Clinics</i> , 2020, 38, 95-113.	0.8	21
85	The Role of Imaging Biomarkers Derived From Advanced Imaging and Radiomics in the Management of Brain Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 559946.	1.3	5
86	Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging Methods in Nonenhancing Gliomas. <i>World Neurosurgery</i> , 2020, 141, 123-130.	0.7	9
87	Better efficacy in differentiating WHO grade II from III oligodendrogliomas with machine-learning than radiologist's reading from conventional T1 contrast-enhanced and fluid attenuated inversion recovery images. <i>BMC Neurology</i> , 2020, 20, 48.	0.8	10
88	Glioblastoma post-operative imaging in neuro-oncology: current UK practice (GIN CUP study). <i>European Radiology</i> , 2021, 31, 2933-2943.	2.3	21
89	Perfusion CT and MR Imaging of the Brain. , 2021, , 203-225.		0
90	Neuroimaging in the Era of the Evolving WHO Classification of Brain Tumors, From the AJR Special Series on Cancer Staging. <i>American Journal of Roentgenology</i> , 2021, 217, 1-13.	1.0	7
91	Prediction of Intraoperative Fluorescence of Brain Gliomas: Correlation between Tumor Blood Flow and the Fluorescence. <i>Journal of Clinical Medicine</i> , 2021, 10, 2387.	1.0	4
92	Functional Imaging-Based Diagnostic Strategy: Intra-axial Brain Masses. , 2011, , 197-220.		6
93	Clinical Applications of MR Perfusion Imaging. , 2011, , 71-105.		2

#	ARTICLE	IF	CITATIONS
94	Clinical MR Biomarkers. Recent Results in Cancer Research, 2020, 216, 719-745.	1.8	2
95	Magnetic Resonance Imaging of the Brain. , 2010, , 107-195.		23
96	Perfusion Imaging by Magnetic Resonance. , 2014, , 341-376.		1
97	Advanced magnetic resonance imaging biomarkers of cerebral metastases. Cancer Imaging, 2012, 12, 245-252.	1.2	13
98	The role of magnetic resonance imaging in the management of brain metastases: diagnosis to prognosis. Cancer Imaging, 2014, 14, 8.	1.2	49
99	Perfusion magnetic resonance imaging changes in normal appearing brain tissue after radiotherapy in glioblastoma patients may confound longitudinal evaluation of treatment response. Radiology and Oncology, 2018, 52, 143-151.	0.6	10
100	Permeability imaging in pediatric brain tumors. Translational Pediatrics, 2014, 3, 218-28.	0.5	7
102	Clinical Applications of Dynamic Contrast-Enhanced (DCE) Permeability Imaging. , 2011, , 117-137.		0
104	Perspectives of 3 T Magnetic Resonance Imaging in Radiosurgical Treatment Planning. Acta Neurochirurgica Supplementum, 2013, 116, 187-191.	0.5	5
105	MR Perfusion Imaging: ASL, T2*-Weighted DSC, and T1-Weighted DCE Methods. , 2014, , 3-25.		0
106	Functional Magnetic Resonance Techniques in CNS Tumors. , 2014, , 553-602.		0
107	The Role of Radiology in Personalized Medicine. Europeanization and Globalization, 2016, , 219-230.	0.1	0
108	3.0T Imaging of Brain Gliomas. , 2017, , 271-319.		0
110	Correlations among Apparent Diffusion Coefficient and Permeability Parameters from Dynamic Contrast-enhanced MR in Brain Tumor Parenchyma and Peritumoral Area. Journal of Neurology & Neurophysiology, 2018, 09, .	0.1	0
111	Diagnostic support of radiosurgery at brain metastases. Radiation Diagnostics Radiation Therapy, 2019, , 58-69.	0.2	1
114	Applications of Quantitative Perfusion and Permeability in the Body. Advances in Magnetic Resonance Technology and Applications, 2020, , 427-454.	0.0	0
115	Is there a Role for Spect with (99m)Tc-Tetrofosmin in the Diagnostic Work Up of a Brain Tumor?. MÃ dica, 2013, 8, 347-50.	0.4	1
116	Advanced Magnetic Resonance Imaging in Pediatric Glioblastomas. Frontiers in Neurology, 2021, 12, 733323.	1.1	11

#	ARTICLE	IF	CITATIONS
117	Dynamic contrast-enhanced magnetic resonance imaging for evaluating early response to radiosurgery in patients with vestibular schwannoma. Japanese Journal of Radiology, 2022, 40, 678-688.	1.0	2
119	Evaluation of normal-appearing white matter with perfusion and diffusion MRI in patients with treated glioblastoma. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 153-162.	1.1	1
120	A prospective study to evaluate the role of multiparametric magnetic resonance imaging in the grading of gliomas using magnetic resonance imaging perfusion and diffusion and multivoxel magnetic resonance spectroscopy. The Journal of Clinical and Scientific Research, 2022, 11, 150.	0.1	0
121	Noninvasive Determination of the IDH Status of Gliomas Using MRI and MRI-Based Radiomics: Impact on Diagnosis and Prognosis. Current Oncology, 2022, 29, 6893-6907.	0.9	9
122	Mapping glioma heterogeneity using multiparametric 18F-choline PET/MRI in childhood and teenage-young adults. Nuclear Medicine Communications, 0, Publish Ahead of Print, .	0.5	1
123	Prognostication of overall survival in patients with brain metastases using diffusion tensor imaging and dynamic susceptibility contrast-enhanced MRI. British Journal of Radiology, 2022, 95, .	1.0	0
124	Efficacy of three-dimensional arterial spin labeling and how it compares against that of contrast enhanced magnetic resonance imaging in preoperative grading of brain gliomas. Environmental Toxicology, 0, , .	2.1	0
125	Clinical Applications of MR Perfusion Imaging. , 2023, , 119-160.		0
126	Functional Imaging-Based Diagnostic Strategy: Intra-axial Brain Masses. , 2023, , 311-343.		0
127	Clinical Applications of Dynamic Contrast-Enhanced (DCE) Permeability Imaging. , 2023, , 175-200.		1
128	Biomarkers in Precision Medicine with Special Reference to Oncology. , 2023, , 173-187.		0